Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

vTv Therapeutics Inc. VTVT NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$51.33
+36.1%

vTv Therapeutics Inc. (VTVT) is a Biotechnology company in the Healthcare sector, currently trading at $37.72. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is VTVT = $51 (+36.1% upside).

Valuation: VTVT trades at a trailing Price-to-Earnings (P/E) of -11.7 (S&P 500 average ~25).

Net income is $27M (loss), growing at -6%/yr. Net profit margin is 0% (thin). Gross margin is 91.2% (-4.2 pp trend).

Balance sheet: total debt is $0 against $64M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 13.54 (strong liquidity). Debt-to-assets is 0%. Total assets: $90M.

Analyst outlook: 7 / 14 analysts rate VTVT as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 41/100 (Fail), Future 64/100 (Pass), Income ?/100 (Fail).

$51.33
▲ 36.08% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for vTv Therapeutics Inc., the average price target is $51.33, with a high forecast of $58.00, and a low forecast of $47.00.
Highest Price Target
$58.00
Average Price Target
$51.33
Lowest Price Target
$47.00

VTVT SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VTVT

✓
VALUE Pass
90/100
VTVT trades at a trailing Price-to-Earnings (P/E) of -11.7 (S&P 500 average ~25). Forward PEG -0.26 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $51, implying +35.2% from the current price $38. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
VTVT: -100%/yr revenue is, -6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet VTVT: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 13.54 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
VTVT: Gross margin is 91.2% (-4.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 7 / 14 analysts rate VTVT as buy (50%). Analyst consensus target is $51 (+35.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range14-44
Volume38.54K
Avg Volume (30D)45.09K
Market Cap$98.72M
Beta (1Y)0.40
Share Statistics
EPS (TTM)-3.20
Shares Outstanding$8.42M
IPO Date2015-07-30
Employees23
CEOPaul J. Sekhri
Financial Highlights & Ratios
Gross Profit$-16K
EBITDA$-32.79M
Net Income$-26.97M
Operating Income$-32.81M
Total Cash$88.93M
Net Debt$-88.93M
Total Assets$89.9M
Price / Earnings (P/E)-11.8
Analyst Forecast
1Y Price Target$49.00
Target High$58.00
Target Low$47.00
Upside+29.9%
Rating ConsensusBuy
Analysts Covering14
Buy 50% Hold 50% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS9183852048

Price Chart

Track all markets on TradingView
VTVT
vTv Therapeutics Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
14.00 52WK RANGE 44.00

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 IMMX
IMMX
Immix Biopharma, Inc.
$10.04
+1.93%
 ZURA
ZURA
Zura Bio Limited
$5.69
-0.52%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.89
+4.90%
 PYXS
PYXS
Pyxis Oncology, Inc.
$1.71
+0.59%
 SGTX
SGTX
Sigilon Therapeutics, Inc.
$22.47
-2.56%
 KRON
KRON
Kronos Bio, Inc.
$0.88
+1.49%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message